Clinical trial · Observational
Dosing and Outcomes Study of Erythropoietic Stimulating Therapies in Patients With Chemotherapy Induced Anemia
Dosing and Outcomes Study of Erythropoietic Stimulating Therapies
NCT00212862CI-TRIAL-00014971DOSEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to describe patient characteristics, treatment patterns, and clinical outcomes in adult patients with cancer who are receiving erythropoiesis-stimulating therapy (EST).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients with chemotherapy induced anemia | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with chemotherapy induced anemia
- interventionNames
- Other: Patients with chemotherapy induced anemia
Primary outcomes (1)
- measure
- To document patient characteristics and patterns of clinical management
- timeFrame
- Up to 3 years
- description
- The clinical management includes changes in chemotherapy, radiation, bleeding, missed EST doses.
Secondary outcomes (2)
- measure
- To assess the relationships between patient characteristics, treatment patterns and outcomes
- timeFrame
- Up to 3 years
- measure
- To measure economic impacts, and quality of life
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with cancer who are being treated with an erythropoiesis-stimulating therapy (EST) for anemia of cancer or cancer-related treatment * Must be EST ''naive'' globally or must have been off treatment with an EST for at least 90 days * Must speak and read english and be able to answer the type of simple questions presented in the patient questionnaires * If the patient is identified for the study while an inpatient, they must be able to be followed for up to 16 weeks * The patient must give consent to participate in the registry by signing the informed consent form Exclusion Criteria: * Patients currently participating in any other clinical study of EST (however, the patient may be undergoing treatment under an investigational cancer treatment protocol) * Have or had been on dialysis for end stage renal disease in the past * Has myelodysplasia or any myelodysplastic syndrome * Patients are known to need stem cell transplant * Patient who will self-administer the epoetin alfa or darbepoetin alfa
References
Publications (1)
- RESULTLarholt K, Pashos CL, Wang Q, Bookhart B, McKenzie RS, Piech CT. Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) : a registry for characterizing anaemia management and outcomes in oncology patients. Clin Drug Investig. 2008;28(3):159-67. doi: 10.2165/00044011-200828030-00003. PMID 18266401